Results 31 to 40 of about 15,370 (316)

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers [PDF]

Clinical Cancer Research, 2016
Abstract Immunotherapy is currently transforming cancer treatment. Notably, immune checkpoint blockers (ICB) have shown unprecedented therapeutic successes in numerous tumor types, including cancers that were traditionally considered as nonimmunogenic. However, a significant proportion of patients do not respond to these therapies. Thus,
Roman M, Chabanon, Marion, Pedrero, Céline, Lefebvre, Aurélien, Marabelle, Jean-Charles, Soria, Sophie, Postel-Vinay   +5 more
openaire   +2 more sources

Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology [PDF]

, 2020
Combination immunotherapy (CIT) is currently applied as a treatment for different cancers and is proposed as a cure strategy for chronic viral infections. Whether such therapies are efficient during an acute infection remains elusive.
Akhmetzyanova, Ilseyar [u.v.m.], David, Paul David, Drabczyk-Pluta, Malgorzata, Gruber, Achim D., Honke, Nadine, Kershaw, Olivia, Knuschke, Torben, Megger, Dominik A., Pastille, Eva, Werner, Tanja   +9 more
core   +1 more source

Novel immune checkpoint blocker to treat Merkel cell carcinoma [PDF]

OncoImmunology, 2017
Over the past few years, immune checkpoint blockers (ICBs) have literally revolutionized the treatment of multiple tumors, including (but not limited to) melanoma, non-small cell lung carcinoma (NS...
Lorenzo Galluzzi, Guido Kroemer
openaire   +3 more sources

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma

Frontiers in Pharmacology, 2022
Peripheral T-cell lymphomas (PTCLs) are highly heterogeneous and present significant treatment challenges. Immune checkpoint therapies, such as PD-1 and CTLA-4 inhibitors, have significantly changed the clinical management paradigm of tumors.
Xi Chen, Wanchun Wu, Wenwen Wei, Liqun Zou   +3 more
doaj   +1 more source

Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort. [PDF]

ESMO Open
Patients with solid organ transplant (SOT) and solid tumors are usually excluded from clinical trials testing immune checkpoint blockers (ICB). As transplant rates are increasing, we aimed to evaluate ICB outcomes in this population, with a special focus on lung cancer.We conducted a multicenter retrospective cohort study collecting real data of ICB ...
Remon J, Auclin E, Zubiri L, Schneider S, Rodriguez-Abreu D, Minatta N, Gautschi O, Aboubakar F, Muñoz-Couselo E, Pierret T, Rothschild SI, Cortiula F, Reynolds KL, Thibault C, Gavralidis A, Blais N, Barlesi F, Planchard D, Besse BMD.   +18 more
europepmc   +6 more sources

Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling

Nature Communications, 2022
Tumor loss of IFN-γ signalling is a major mechanism of resistance to immune checkpoint blockers. Here the authors report that melanoma cells with knockout of IFNγR1 show constitutive JAK1/2 activation and that the JAK1/2 inhibitor ruxolitinib can ...
Hongxing Shen, Fengyuan Huang, Xiangmin Zhang, Oluwagbemiga A. Ojo, Yuebin Li, Hoa Quang Trummell, Joshua C. Anderson, John Fiveash, Markus Bredel, Eddy S. Yang, Christopher D. Willey, Zechen Chong, James A. Bonner, Lewis Zhichang Shi   +13 more
doaj   +1 more source

Understanding genetic determinants of resistance to immune checkpoint blockers

Seminars in Cancer Biology, 2020
The advent of immune checkpoint blockers (ICB) has revolutionized patient outcome in many tumor types. However, only a minority of patients truly benefits from these therapies and displays a durable and robust anti-tumor response that translates into improved outcome.
Sandrine, Aspeslagh, Roman M, Chabanon, Stéphane, Champiat, Sophie, Postel-Vinay   +3 more
openaire   +4 more sources

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [PDF]

, 2017
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
Abdallah, K., Anderson, J., Andrews, S., Arrindell, D., Ballesteros, J., Bingham, C. O., Boyer, J., Brogdon, C., Chen, D., Chonzi, D., Cotarla, I., Cunha, R., Dadu, R., Davies, M., Dawson, M., Diab, A., Dicker, Adam, Eifler, L., Ernstoff, M. S., Ferguson, A., Ferlini, C., Frankel, S., Go, W., Gochett, C., Goldberg, J., Goncalves, P., Goswami, T., Gregory, N., Gulley, J. L., Hamad, L., Hayreh, V., Helie, N., Holmes, W., Hsu, J. Y., Ibrahim, R., Kaufman, H. L., Kim, S., Lacouture, M. E., Lambotte, O., Larocca, C., LeBoeuf, N. R., Lehman, K., Lenihan, D., Ley-Acosta, S., Luke, J., McClure, J., Michelon, E., Nakamura, M., Onofrei, C., Patel, K., Piperdi, B., Puzanov, I., Rasheed, Z., Reshef, D., Riemer, J., Robert, C., Sarkeshik, M., Saylors, A., Schreiber, J., Shafer-Weaver, K., Shannon, V., Sharfman, W., Sharma, R., Sharon, E., Sherry, R., Silk, A. W., Simonson, C., Skondra, D., Suarez-Almazor, M. E., Thomas, C., Thompson, J. A., Trehu, E., Tresnan, D., Turner, M., Wang, Y., Wariabharaj, D., Waxman, I., Wiley, K., Wood, L., Zhang, L., Zheng, P.   +80 more
core   +2 more sources

The Cellular and Molecular Immunotherapy in Prostate Cancer

Vaccines, 2022
In recent history, immunotherapy has become a viable cancer therapeutic option. However, over many years, its tenets have changed, and it now comprises a range of cancer-focused immunotherapies. Clinical trials are currently looking into monotherapies or
Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, D. S. Prabakaran, Raja Ganesan, Kaviyarasi Renu, Abhijit Dey, Balachandar Vellingiri, Sabariswaran Kandasamy, Thiyagarajan Ramesh, Abilash Valsala Gopalakrishnan   +9 more
doaj   +1 more source

Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker [PDF]

Cancer Medicine, 2020
AbstractImmunocheckpoint proteins of tumor infiltrating lymphocytes play an important role in tumor prognosis in the course of tumor clinicopathology. PD‐1 (Programmed cell death protein 1) is an important immunosuppressive molecule. By binding to PD‐L1 (programmed cell death‐ligand 1), it blocks TCR and its costimulus signal transduction, inhibits the
Zhengyi Wang, Xiaoying Wu
openalex   +4 more sources